Cancer immunotherapies, such as immune checkpoint blockade (ICB), have been used in a
wide range of tumor types with immense clinical benefit. However, ICB does not work in all
patients, and attempts to combine ICB with other immune-based therapies have not lived up
to their initial promise. Thus, there is a significant unmet need to discover new targets and
combination therapies to extend the benefits of immunotherapy to more patients. Systems
biology approaches are well suited for addressing this problem because these approaches …